# HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)

> **NCT02437110** · PHASE1 · COMPLETED · sponsor: **National Institute of Neurological Disorders and Stroke (NINDS)** · enrollment: 122 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** Darunavir
- **DRUG:** Ritonavir
- **DRUG:** Dolutegravir
- **DRUG:** Tenofovir alafenamide (TAF)

## Key facts

- **NCT ID:** NCT02437110
- **Lead sponsor:** National Institute of Neurological Disorders and Stroke (NINDS)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-01
- **Primary completion:** 2022-11-17
- **Final completion:** 2023-05-09
- **Target enrollment:** 122 (ACTUAL)
- **Last updated:** 2024-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02437110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02437110, "HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02437110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*